Form 4: Elanco Executive Kinard Boosts Stake with Equity Grants
Insider Transaction Report
Elanco Animal Health's EVP, David S. Kinard, received significant equity compensation, including restricted stock units and stock options, increasing his beneficial ownership.
Summary
- David S. Kinard, Executive Vice President, Human Resources, Corporate Affairs and Administration at Elanco Animal Health Inc., reported several transactions on March 1, 2026.
- Kinard acquired 33,087 shares of common stock at a price of $0, bringing his beneficial ownership to 223,604 shares.
- This acquisition includes 648 shares acquired on April 30, 2025, 518 shares on July 31, 2025, 221 shares on October 31, 2025, and 252 shares on January 31, 2026, through the Employee Stock Purchase Plan.
- He disposed of 15,377 shares of common stock at $26.4 per share, resulting in 208,227 shares beneficially owned.
- Kinard also acquired an additional 9,470 shares of common stock at $0, which are restricted stock units vesting one-third annually on March 1, 2027, March 1, 2028, and March 1, 2029.
- Additionally, he was granted 19,350 employee stock options with an exercise price of $26.4, vesting one-third annually on March 1, 2027, March 1, 2028, and March 1, 2029, and expiring on March 1, 2036.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a substantial equity grant to a key executive, reinforcing alignment between management's interests and long-term shareholder value. The disposition is likely tax-related and not indicative of a negative sentiment.
Positives
- David S. Kinard received a grant of 33,087 shares of common stock at $0, increasing his direct beneficial ownership.
- An additional grant of 9,470 restricted stock units (RSUs) at $0 further aligns Kinard's interests with shareholders, vesting over three years.
- The grant of 19,350 employee stock options with an exercise price of $26.4 provides a long-term incentive for Kinard, vesting over three years and expiring in 2036.
- The overall increase in Kinard's potential equity stake demonstrates continued commitment from a key executive.
Negatives
- Kinard disposed of 15,377 shares of common stock at $26.4 per share, which likely represents shares withheld for tax obligations related to equity compensation.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that equity grants to senior executives are a standard practice across the animal health and broader pharmaceutical industries, serving to align management incentives with long-term shareholder value creation. These grants are typical components of executive compensation packages designed to retain talent and encourage performance.
Related Party Transactions
- The reported transactions involve equity compensation granted by Elanco Animal Health Inc. to its Executive Vice President, David S. Kinard, which are considered related party transactions under SEC rules.
Stakeholder Impact
- Shareholders: The grants align the executive's financial interests with long-term company performance, potentially benefiting shareholders through improved management incentives.
- Employees: The Employee Stock Purchase Plan (ESPP) acquisitions mentioned in the footnotes indicate broader employee participation in company ownership, which can boost morale and retention.
- Management: The executive receives significant equity compensation, enhancing their personal wealth potential tied to the company's success.
Next Steps
- The restricted stock units and stock options will vest in three annual installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Acquisition of 648 shares under Elanco's Employee Stock Purchase Plan. |
| 07/31/2025 | Acquisition of 518 shares under Elanco's Employee Stock Purchase Plan. |
| 10/31/2025 | Acquisition of 221 shares under Elanco's Employee Stock Purchase Plan. |
| 01/31/2026 | Acquisition of 252 shares under Elanco's Employee Stock Purchase Plan. |
| 03/01/2026 | Transaction date for acquisition of 33,087 common shares, disposition of 15,377 common shares, acquisition of 9,470 restricted stock units, and grant of 19,350 employee stock options. |
| 03/03/2026 | Signature date of the reporting person's attorney-in-fact. |
| 03/01/2027 | First vesting date for one-third of the restricted stock units and stock options granted. |
| 03/01/2028 | Second vesting date for one-third of the restricted stock units and stock options granted. |
| 03/01/2029 | Final vesting date for the remaining one-third of the restricted stock units and stock options granted. |
| 03/01/2036 | Expiration date for the employee stock options granted. |
Recommendation
holdThis Form 4 filing details routine executive compensation through equity grants and a related tax withholding transaction. While the grants are positive for management alignment and retention, they do not fundamentally alter the company's financial outlook or strategic direction to warrant a strong buy or sell recommendation. A seasoned investor would likely maintain their current position, viewing this as an expected part of executive compensation.
Keywords
Elanco Animal Health, ELAN, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Stock Options, Executive Compensation, Beneficial Ownership, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.